Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00089596 · ClinicalTrials.gov registry record · Phase 1

Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by ViaCell.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
4
Study locations

NCT00089596 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome that has completed, run by ViaCell. The registered enrollment target is 10 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00089596, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, has completed, sponsored by ViaCell.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
4
Study locations

Study Summary

This study hopes to show that specially treated umbilical cord cells, called stem cells, can be safely given to a person after they receive chemoradiation therapy or chemotherapy for their illness. During chemoradiation therapy or chemotherapy, a person loses all of the cells that are needed to make the different types of cells in their blood, including their immune system cells. These cells must be replaced in order for the blood and immune systems to work properly. Some people receive bone marrow transplants or other types of stem cell transplants to get the cells they need. CB001 is being developed as an option for people who need bone marrow transplants or other types of transplants to replace those cells. It is also being developed for people who do not have the option of other types of transplants.

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndrome Non-Hodgkin Lymphoma Chronic Myelogenous Leukemia Acute Lymphocytic Leukemia

Interventions

  • PROCEDURE Expansion of umbilical cord stem cells

Study Locations (4)

Illinois

  • Loyola University Medical Center - Maywood

Indiana

  • Indiana University Cancer Center - Indianapolis

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2004-03
Est. Completion 2006-10
Phase Phase 1

Sponsor

ViaCell

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00089596

The ClinicalTrials.gov registry entry for NCT00089596 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (91% lower). The listed sponsor is ViaCell, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Expansion of umbilical cord stem cells is the first listed.

NCT00089596 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Indiana, New Jersey.

Frequently Asked Questions

What is clinical trial NCT00089596 about?

NCT00089596 is a clinical study titled "Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers". This study hopes to show that specially treated umbilical cord cells, called stem cells, can be safely given to a person after they receive chemoradiation therapy or chemotherapy for their illness. During chemoradiation therapy or chemotherapy, a person loses all of the cells that are needed to make...

What is the current status of trial NCT00089596?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2004-03. Estimated completion is 2006-10.

What conditions does trial NCT00089596 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia, Acute Lymphocytic Leukemia.

What interventions are being tested in trial NCT00089596?

The interventions under investigation include: Expansion of umbilical cord stem cells (PROCEDURE).

Who is sponsoring clinical trial NCT00089596?

This trial is sponsored by ViaCell, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00089596 being conducted?

This trial has 4 study locations across Illinois, Indiana, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndrome

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.